行情

ZIOP

ZIOP

ZIOPHARM肿瘤
NASDAQ

实时行情|Nasdaq Last Sale

2.390
+0.190
+8.64%
盘后: 2.390 0 0.00% 17:10 04/02 EDT
开盘
2.200
昨收
2.200
最高
2.390
最低
2.130
成交量
164.37万
成交额
--
52周最高
7.25
52周最低
1.795
市值
5.09亿
市盈率(TTM)
-3.4344
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ZIOP价格均价为5.92,最高价位7.50,最低价为3.000。

EPS

ZIOP 新闻

更多
  • Benzinga's Top Upgrades, Downgrades For March 4, 2020
  • Benzinga · 03/04 15:08
  • Cantor Fitzgerald Initiates Coverage On ZIOPHARM Oncology with Overweight Rating, Announces $6 Price Target
  • Benzinga · 03/04 10:10
  • Ziopharm down 6% despite pipeline advancement and cash influx
  • Seeking Alpha - Article · 03/03 16:15
  • Raymond James Maintains Outperform on ZIOPHARM Oncology, Lowers Price Target to $5.5
  • Benzinga · 03/03 12:34

所属板块

生物技术和医学研究
+3.32%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

ZIOP 简况

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
展开

微牛提供ZIOPHARM Oncology Inc.(NASDAQ-ZIOP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ZIOP股票新闻,以帮助您做出投资决策。